Patent Application
20150005281
The present invention relates to a novel class of kinase inhibitors, including pharmaceutically acceptable salts, prodrugs and metabolites thereof, which are useful for modulating protein kinase activity for modulating cellular activities such as signal transduction, proliferation, and cytokine secretion. More specifically the invention provides compounds which inhibit, regulate and/or modulate kinase activity, in particular JAK activity, and signal transduction pathways relating to cellular activities as mentioned above. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds, for example for the treatment or prevention of an immunological, inflammatory, autoimmune, or allergic disorder or disease or a transplant rejection or a Graft-versus host disease and processes for preparing said compounds.
Kinases catalyze the phosphorylation of proteins, lipids, sugars, nucleosides and other cellular metabolites and play key roles in all aspects of eukaryotic cell physiology. Especially, protein kinases and lipid kinases participate in the signaling events which control the activation, growth, differentiation and survival of cells in response to extracellular mediators or stimuli such as growth factors, cytokines or chemokines. In general, protein kinases are classified in two groups, those that preferentially phosphorylate tyrosine residues and those that preferentially phosphorylate serine and/or threonine residues. The tyrosine kinases include membrane-spanning growth factor receptors such as the epidermal growth factor receptor (EGFR) and cytosolic non-receptor kinases such as Janus kinases (JAK).
Inappropriately high protein kinase activity is involved in many diseases including cancer, metabolic diseases, autoimmune or inflammatory disorders. This effect can be caused either directly or indirectly by the failure of control mechanisms due to mutation, overexpression or inappropriate activation of the enzyme. In all of these instances, selective inhibition of the kinase is expected to have a beneficial effect.
One group of kinases that has become a recent focus of drug discovery is the Janus kinase (JAK) family of non-receptor tyrosine kinases. In mammals, the family has four members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2). Each protein has a kinase domain and a catalytically inactive pseudo-kinase domain. The JAK proteins bind to cytokine receptors through their amino-terminal FERM (Band-4.1, ezrin, radixin, moesin) domains. After the binding of cytokines to their receptors, JAKs are activated and phosphorylate the receptors, thereby creating docking sites for signalling molecules, especially for members of the signal transducer and activator of transcription (Stat) family (Yamaoka et al., 2004. The Janus kinases (Jaks). Genome Biology 5(12): 253).
In mammals, JAK1, JAK2 and TYK2 are ubiquitously expressed. By contrast, the expression of JAK3 is predominantly in hematopoietic cells and it is highly regulated with cell development and activation (Musso et al., 1995. 181(4):1425-31).
The study of JAK-deficient cell lines and gene-targeted mice has revealed the essential, nonredundant functions of JAKs in cytokine signalling. JAK1 knockout mice display a perinatal lethal phenotype, probably related to the neurological effects that prevent them from sucking (Rodig et al., 1998. Cell 93(3):373-83). Deletion of the JAK2 gene results in embryonic lethality at embryonic day 12.5 as a result of a defect in erythropoiesis (Neubauer et al., 1998. Cell 93(3):397-409). Interestingly, JAK3 deficiency was first identified in humans with autosomal recessive severe combined immunodeficiency (SCID) (Macchi et al., 1995. Nature 377(6544):65-68). JAK3 knockout mice too exhibit SCID but do not display non-immune defects, suggesting that an inhibitor of JAK3 as an immunosuppressant would have restricted effects in vivo and therefore presents a promising drug for immunosuppression (Papageorgiou and Wikman 2004, Trends in Pharmacological Sciences 25(11):558-62).
Activating mutations for JAK3 have been observed in acute megakaryoblastic leukemia (AMKL) patients (Walters et al., 2006. Cancer Cell 10(1):65-75). These mutated forms of JAK3 can transform Ba/F3 cells to factor-independent growth and induce features of megakaryoblastic leukemia in a mouse model.
Diseases and disorders associated with JAK3 inhibition are further described, for example in WO 01/42246 and WO 2008/060301.
Several JAK3 inhibitors have been reported in the literature which may be useful in the medical field (O'Shea et al., 2004. Nat. Rev. Drug Discov. 3(7):555-64). A potent JAK3 inhibitor (CP-690,550) was reported to show efficacy in an animal model of organ transplantation (Changelian et al., 2003, Science 302(5646):875-888) and clinical trials (reviewed in: Pesu et al., 2008. Immunol. Rev. 223, 132-142). The CP-690,550 inhibitor is not selective for the JAK3 kinase and inhibits JAK2 kinase with almost equipotency (Jiang et al., 2008, J. Med. Chem. 51(24):8012-8018). It is expected that a selective JAK3 inhibitor that inhibits JAK3 with greater potency than JAK2 may have advantageous therapeutic properties, because inhibition of JAK2 can cause anemia (Ghoreschi et al., 2009. Nature Immunol. 4, 356-360).
Pyrimidine compounds are described in WO 2004/056785 A2, WO 2004/056786 A2, WO 2004/056807 A1, WO 2005/111022 A1, US 2005/256145A1, WO 2007/072158 A2, WO 2009/145856 A1, WO 2010/083207 A2.
Pyrimidine derivatives exhibiting JAK3 and JAK2 kinase inhibiting activities are described in WO-A 2008/009458. Pyrimidine compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3 are described in WO-A 2008/118822 and WO-A 2008/118823.
Fluoro substituted pyrimidine compounds as JAK3 inhibitors are described in WO-A 2010/118986. Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors are described in WO-A 2011/048082.
WO-A 2008/129380 relates to sulfonyl amide derivatives for the treatment of abnormal cell growth.
JAK inhibitors are described in WO-A 2010/118986, WO-A 2011/029807, WO-A 2011/048082, WO-A 2012/022681, and WO-A 2011/134831. Further JAK3 inhibitors are described in International patent applications with application No PCT/EP2012/056887, PCT/EP2012/064515, PCT/EP2012/064510, PCT/EP2012/064512, and PCT/EP2012/068504.
JAK inhibitors are described in WO-A 2010/129802 wherein the substituent off the pyrimidine core (corresponding to X in formula (I) below) is restricted to an amide. Examples such as 66 and 330 wherein the equivalent group to TOB of formula (I) below contains a saturated (hetero)cycle do not generate potent and selective JAK family inhibitors. WO-A 2007/146981 describes inhibitors of Protein Kinase C-alpha. Charles L. Cywin et al., Bioorganic and Medicinal Chemistry Letters, vol 17, no 1, January 2007, 225-230, describes inhibitors of PKC-theta wherein the preferred substituent off the pyrimidine core (corresponding to X in formula (I) below) is a nitro group. Nitro groups are not typically associated with drug-like properties. DE-A 10 2007 010 801 describes compounds wherein the residue corresponding to T0B in formula (I) below is a cyclopropyl group as herbicides. WO-A 2010/025851 describes compounds where at least one of the ring atoms in the ring corresponding to TOA in formula (I) below is a sulfur atom as herbicides. WO-A 2010/146133 describes compounds as ZAP70 and JAK3 inhibitors.
TYK2 inhibitors are described in international patent applications WO-A 2012/000970 and WO-A 2012/062704.
Even though JAK inhibitors are known in the art there is a need for providing additional JAK inhibitors having at least partially more effective pharmaceutically relevant properties, like activity, selectivity especially over JAK2 kinase, and ADME properties.
Thus, an object of the present invention is to provide a new class of compounds as JAK inhibitors which preferably show selectivity over JAK2 and may be effective in the treatment or prophylaxis of disorders associated with JAK.
Accordingly, the present invention provides compounds of formula (I)
or a pharmaceutically acceptable salt thereof, wherein
R is H; or C1-4 alkyl, wherein C1-4 alkyl is optionally substituted with one or more halogen, which are the same or different;
T0A is phenyl, naphthyl, or aromatic 5 to 6 membered heterocyclyl, wherein T0A is optionally substituted with one or more (preferably unsubstituted; or substituted with one, two, or three; more preferably substituted with one or two, even more preferably one) R1;
Each R1 is independently halogen; CN; C(O)OR2; OR2; C(O)R2; C(O)N(R2R2a); S(O)2N(R2R2a); S(O)N(R2R2a); S(O)2R2; S(O)R2; N(R2)S(O)2N(R2aR2b); N(R2)S(O)N(R2aR2b); SR2; N(R2R2a); NO2; OC(O)R2; N(R2)C(O)R2a; N(R2)S(O)2R2a; N(R2)S(O)R2a; N(R2)C(O)N(R2aR2b); N(R2)C(O)OR2a; OC(O)N(R2R2a); T1; C1-6 alkyl; C2-6 alkenyl; or C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more (preferably unsubstituted or substituted with one, two, or three; even more preferably, unsubstituted or substituted with one, or two; even more preferably, unsubstituted or substituted with one) R3, which are the same or different;
R2, R2a, R2b are independently selected from the group consisting of H; T1; C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R3, which are the same or different;
R3 is halogen; CN; C(O)OR4; OR4; C(O)R4; C(O)N(R4R4a); S(O)2N(R4R4a); S(O)N(R4R4a); S(O)2R4; S(O)R4; N(R4)S(O)2N(R4aR4b); N(R4)S(O)N(R4aR4b); SR4; N(R4R4a); NO2; OC(O)R4; N(R4)C(O)R4a; N(R4)S(O)2R4a; N(R4)S(O)R4a; N(R4)C(O)N(R4aR4); N(R4)C(O)OR4a; OC(O)N(R4R4a); or T1;
R4, R4a, R4b are independently selected from the group consisting of H; T1; C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
T1 is C3-7 cycloalkyl; saturated 4 to 7 membered heterocyclyl; or saturated 7 to 11 membered heterobicyclyl, wherein T1 is optionally substituted with one or more R10, which are the same or different;
R5, R5a are independently selected from the group consisting of H; and unsubstituted C1-6 alkyl; or jointly form oxo (═O);
Optionally, R5, R5a are joined to form an unsubstituted C3-7 cycloalkyl;
T0B is C3-7 cycloalkyl; or saturated 4 to 7 membered heterocyclyl, wherein T0B is optionally substituted with one or more (preferably unsubstituted; or substituted with one, two, or three; more preferably unsubstituted or substituted with one or two, even more preferably unsubstituted or substituted with one) R6, which are the same or different;
R6 is halogen; CN; C(O)OR7; OR7; oxo (═O); C(O)R7; C(O)N(R7R7a); S(O)2N(R7R7a); S(O)N(R7R7a); S(O)2R7; S(O)R7; N(R7)S(O)2N(R7aR7b); N(R7)S(O)N(R7aR7b); SR7; N(R7R7a); NO2; OC(O)R7; N(R7)C(O)R7a; N(R7)S(O)2R7a; N(R7)S(O)R7a; N(R7)C(O)N(R7aR7b); N(R7)C(O)OR7a; OC(O)N(R7R7a); T2; C1-6 alkyl; C2-6 alkenyl; or C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R11, which are the same or different;
R7, R7a, R7b are independently selected from the group consisting of H; T2; C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R8, which are the same or different;
R8 is halogen; CN; C(O)OR9; OR9; C(O)R9; C(O)N(R9R9a); S(O)2N(R9R9a); S(O)N(R9R9a); S(O)2R9; S(O)R9; N(R9)S(O)2N(R9aR9b); N(R9)S(O)N(R9aR9b); SR9; N(R9R9a); NO2; OC(O)R9; N(R9)C(O)R9a; N(R9)S(O)2R9a; N(R9)S(O)R9a; N(R9)C(O)N(R9aR9b); N(R9)C(O)OR9a; OC(O)N(R9R9a); or T2;
R9, R9a, R9b are independently selected from the group consisting of H; T2; C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R12, which are the same or different;
R10 is halogen; CN; C(O)OR13; OR13; oxo (═O), where the ring is at least partially saturated; C(O)R13; C(O)N(R13R13a); S(O)2N(R13R13a); S(O)N(R13R13a); S(O)2R13; S(O)R13; N(R13)S(O)2N(R13aR13b); N(R13)S(O)N(R13aR13b); SR13; N(R13R13a); NO2; OC(O)R13; N(R13)C(O)R13a; N(R13)S(O)2R13a; N(R13)S(O)R13a; N(R13)C(O)N(R13aR13b); N(R13)C(O)OR13a; OC(O)N(R13R13a); C1-6 alkyl; C2-6 alkenyl; or C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R14, which are the same or different;
R13, R13a, R13b are independently selected from the group consisting of H; C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R14, which are the same or different;
R11, R12 are independently selected from the group consisting of halogen; CN; C(O)OR15; OR15; C(O)R15; C(O)N(R15R15a); S(O)2N(R15R15a); S(O)N(R15R15a); S(O)2R15; S(O)R15; N(R15)S(O)2N(R15aR15b); N(R15)S(O)N(R15aR15b); SR15; N(R15R15a); NO2; OC(O)R15; N(R15)C(O)R15a; N(R15)S(O)2R15a; N(R15)S(O)R15a; N(R15)C(O)N(R15aR15b); N(R15)C(O)OR15a; OC(O)N(R15R15a); and T2;
R15, R15a, R15b are independently selected from the group consisting of H; T2; C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more substituents selected from the group consisting of halogen and CN (preferably, optionally substituted with one or more halogen, which are the same or different);
R14 is halogen; CN; C(O)OR16; OR16; C(O)R16; C(O)N(R16R16a); S(O)2N(R16R16a); S(O)N(R16R16a); S(O)2R16; S(O)R16; N(R16)S(O)2N(R16aR16); N(R16)S(O)N(R16aR16b); SR16; N(R16R16a); NO2; OC(O)R16; N(R16)C(O)R16a; N(R16)S(O)2R16a; N(R16)S(O)R16a; N(R16)C(O)N(R16aR16b); N(R16)C(O)OR16a; or OC(O)N(R16R16a);
R16, R16a, R16b are independently selected from the group consisting of H; C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more halogen, which are the same or different;
T2 is phenyl; naphthyl; indenyl; indanyl; C3-7 cycloalkyl; 4 to 7 membered heterocyclyl; or 7 to 11 membered heterobicyclyl, wherein T2 is optionally substituted with one or more R17, which are the same or different;
R17 is halogen; CN; C(O)OR18; OR18; oxo (═O), where the ring is at least partially saturated; C(O)R18; C(O)N(R18R18a); S(O)2N(R18R18a); S(O)N(R18R18a); S(O)2R18; S(O)R18; N(R18)S(O)2N(R18aR18b); N(R18)S(O)N(R18aR18b); SR18; N(R18R18a); NO2; OC(O)R18; N(R18)C(O)R18a; N(R18)S(O)2R18a; N(R18)S(O)R18a; N(R18)C(O)N(R18aR18b); N(R18)C(O)OR18a; OC(O)N(R18R18a); C1-6 alkyl; C2-6 alkenyl; or C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R19, which are the same or different;
R18, R18a, R18b are independently selected from the group consisting of H; C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more R19, which are the same or different;
R19 is halogen; CN; C(O)OR20; OR20; C(O)R20; C(O)N(R20R20a); S(O)2N(R20R20a); S(O)N(R20R20a); S(O)2R20; S(O)R20; N(R20)S(O)2N(R20aR20b); N(R20)S(O)N(R20aR20b); SR20; N(R20R20a); NO2; OC(O)R20; N(R20)C(O)R20a; N(R20)S(O)2R20a; N(R20)S(O)R20a; N(R20)C(O)N(R20aR20b); N(R20)C(O)OR20a; or OC(O)N(R20R20a);
R20, R20a, R20b are independently selected from the group consisting of H; C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl, wherein C1-6 alkyl; C2-6 alkenyl; and C2-6 alkynyl are optionally substituted with one or more halogen, which are the same or different.
Surprisingly it was found that—without being bound by theory—compounds of the present invention may act as kinase inhibitors that form a covalent bond with their protein target and therefore may have advantageous properties compared to non-covalent inhibitors because they may bind irreversibly to their target protein and inactivate it permanently. After irreversible inhibition of the target, a re-synthesis of the protein may be necessary to restore its function. Therefore, the prolonged duration of the drug action may uncouple the pharmacodynamics of the drug from the pharmacokinetic exposure (Singh et al., 2011. Nat. Rev. Drug Discov. 10(4): 307-317; Singh et al., 2010. Curr. Opin. Chem. Biol. 14(4):475-480).
In case a variable or substituent can be selected from a group of different variants and such variable or substituent occurs more than once the respective variants can be the same or different.
Within the meaning of the present invention the terms are used as follows:
The term “optionally substituted” means unsubstituted or substituted. Generally—but not limited to—, “one or more substituents” means one, two or three, preferably one or two and more preferably one. Generally these substituents can be the same or different.
“Alkyl” means a straight-chain or branched hydrocarbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent as further specified herein.
“Alkenyl” means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon double bond. Each hydrogen of an alkenyl carbon may be replaced by a substituent as further specified herein.
“Alkynyl” means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon triple bond. Each hydrogen of an alkynyl carbon may be replaced by a substituent as further specified herein.
“C1-4 alkyl” means an alkyl chain having 1-4 carbon atoms, e.g. if present at the end of a molecule: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or e.g. —CH2—, —CH2—CH2—, —CH(CH3)—, —CH2—CH2—CH2—, —CH(C2H5)—, —C(CH3)2—, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a C1-4 alkyl carbon may be replaced by a substituent as further specified herein.
“C1-6 alkyl” means an alkyl chain having 1-6 carbon atoms, e.g. if present at the end of a molecule: C1-4 alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl; tert-butyl, n-pentyl, n-hexyl, or e.g. —CH2—, —CH2—CH2—, —CH(CH3)—, —CH2—CH2—CH2—, —CH(C2H5)—, —C(CH3)2—, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a C1-6 alkyl carbon may be replaced by a substituent as further specified herein.
“C2-6 alkenyl” means an alkenyl chain having 2 to 6 carbon atoms, e.g. if present at the end of a molecule: —CH═CH2, —CH═CH—CH3, —CH2—CH═CH2, —CH═CH—CH2—CH3, —CH═CH—CH═CH2, or e.g. —CH═CH—, when two moieties of a molecule are linked by the alkenyl group. Each hydrogen of a C2-6 alkenyl carbon may be replaced by a substituent as further specified herein.
“C2-6 alkynyl” means an alkynyl chain having 2 to 6 carbon atoms, e.g. if present at the end of a molecule: —C≡CH, —CH2—C≡CH, CH2—CH2—C≡CH, CH2—C≡C—CH3, or e.g. —C≡C— when two moieties of a molecule are linked by the alkynyl group. Each hydrogen of a C2-6 alkynyl carbon may be replaced by a substituent as further specified herein.
“C3-7 cycloalkyl” or “C3-7 cycloalkyl ring” means a cyclic alkyl chain having 3-7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Preferably, cyloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent as further specified herein. The term “C3-5 cycloalkyl” or “C3-5 cycloalkyl ring” is defined accordingly.
“Halogen” means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.
“4 to 7 membered heterocyclyl” or “4 to 7 membered heterocycle” means a ring with 4, 5, 6 or 7 ring atoms that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 4 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 4 to 7 membered heterocycles are azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine, tetrazolidine, diazepane, azepine or homopiperazine. The term “5 to 6 membered heterocyclyl” or “5 to 6 membered heterocycle” is defined accordingly.
“Saturated 4 to 7 membered heterocyclyl” or “saturated 4 to 7 membered heterocycle” means fully saturated “4 to 7 membered heterocyclyl” or “4 to 7 membered heterocycle”.
“5 membered aromatic heterocyclyl” or “5 membered aromatic heterocycle” means a heterocycle derived from cyclopentadienyl, where at least one carbon atom is replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—). Examples for such heterocycles are furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, triazole, tetrazole. The term “aromatic 5 to 6 membered heterocyclyl” is defined accordingly.
“7 to 11 membered heterobicyclyl” or “7 to 11 membered heterobicycle” means a heterocyclic system of two rings with 7 to 11 ring atoms, where at least one ring atom is shared by both rings and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 7 to 11 membered heterobicycle are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydro quinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine. The term 7 to 11 membered heterobicycle also includes spiro structures of two rings like 1,4-dioxa-8-azaspiro[4.5]decane 2-oxa-6-azaspiro[3.3]heptan-6-yl or 2,6-diazaspiro[3.3]heptan-6-yl or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane or 2,5-diazabicyclo[2.2.2]octan-2-yl.
“Saturated 7 to 11 membered heterobicyclyl” or “saturated 7 to 11 membered heterobicycle” means fully saturated “7 to 11 membered heterobicyclyl” or “7 to 11 membered heterobicycle”.
In case a variable or substituent can be selected from a group of different variants and such variable or substituent occurs more than once the respective variants can be the same or different.
Preferred compounds of formula (I) are those compounds in which one or more of the residues contained therein have the meanings given below, with all combinations of preferred substituent definitions being a subject of the present invention. With respect to all preferred compounds of the formula (I) the present invention also includes all tautomeric and stereoisomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts.
In preferred embodiments of the present invention, the substituents mentioned below independently have the following meaning. Hence, one or more of these substituents can have the preferred or more preferred meanings given below.
Preferably, T0A in formula (I) is defined to give formula (Ia)
wherein Z1, Z2 and Z3 are independently selected from the group consisting of C(R1), N, N(R1), O and S, provided that at least one of Z1, Z2, Z3 is N; and wherein R, Y0, X and T0B are defined as indicated above. More preferably, Z1, Z2, Z3 in formula (Ia) are defined to give formula (Ib)
wherein R, R1, Y0, X and T0B are defined as indicated above.
Preferably, R1 is unsubstituted C1-4 alkyl; or C1-4 alkyl, substituted with OR4 or halogen. Preferably, R1 is unsubstituted C1-4 alkyl (more preferably methyl); or C1-4 alkyl, substituted with OR4 (more preferably, CH2CH2OR4; even more preferably, CH2CH2OH).
Preferably, X is Cl; F; H; or CH3. Preferably, X is Cl, F or CH3. Preferably, X is CF3.
Preferably, R is H.
Preferably, Y0 is CH2.
Preferably, T0B is piperidinyl; pyrrolidinyl; azetidinyl; morpholino; tetrahydropyranyl; or cyclohexyl (more preferably piperidinyl; pyrrolidinyl; azetidinyl; tetrahydropyranyl; or cyclohexyl, also more preferably piperidinyl; pyrrolidinyl; azetidinyl; or morpholino), wherein T0B is unsubstituted or substituted with one or more (preferably unsubstituted; or substituted with one, two, or three; more preferably unsubstituted or substituted with one or two, even more preferably unsubstituted or substituted with one) R6, which are the same or different.
More preferably, T0B is selected from the group consisting of
Preferably, R6 is C(O)R7; N(R7)C(O)R7a; S(O)2R7; or N(R7)S(O)2R7a.
Preferably, R6 is N(R7)C(O)C(R8a)═C(R8bR8c); N(R7)S(O)2C(R8a)═C(R8bR8c); N(R7)C(O)C≡C(R8a); C(O)C(R8a)═C(R8bR8c); S(O)2C(R8a)═C(R8bR8c); or C(O)C≡C(R8a) and wherein R8a, R8b, R8c are independently selected from the group consisting of H; and R8. Preferably, R6 is N(R7)C(O)C(R8a)═C(R8bR8c); N(R7) S(O)2C(R8a)═C(R8bR8c); or N(R7)C(O)C≡C(R8a), wherein R8a, R8b, R8c are independently selected from the group consisting of H; and R8.
Preferably, R6 is C(O)—C1-4 alkyl; or S(O)2—C1-4 alkyl, wherein C1-4 alkyl is optionally substituted with one or more R8, which are the same or different.
Preferably, R6 is C1-4 alkyl wherein C1-4 alkyl is optionally substituted with one or more R11, which are the same or different.
Preferably, R6 is C(O)CH3; C(O)CH═CH2; S(O)2CH3; or S(O)2CH═CH2.
Compounds of formula (I) in which some or all of the above-mentioned groups have the preferred meanings are also an object of the present invention.
Further preferred compounds of the present invention are selected from the group consisting of
Further preferred compounds of the present invention are selected from the group consisting of
Where tautomerism, e.g. keto-enol tautomerism, of compounds of general formula (I) may occur, the individual forms, e.g. the keto and enol form, are comprised separately and together as mixtures in any ratio. The same applies for stereoisomers, e.g. enantiomers, cis/trans isomers, conformers and the like.
Isotopic labeled compounds (“isotopic derivatives”) of formula (I) are also within the scope of the present invention. Methods for isotope labeling are known in the art. Preferred isotopes are those of the elements H, C, N, O and S.
If desired, isomers can be separated by methods well known in the art, e.g. by liquid chromatography. The same applies for enantiomers by using e.g. chiral stationary phases. Additionally, enantiomers may be isolated by converting them into diastereomers, i.e. coupling with an enantiomerically pure auxiliary compound, subsequent separation of the resulting diastereomers and cleavage of the auxiliary residue. Alternatively, any enantiomer of a compound of formula (I) may be obtained from stereoselective synthesis using optically pure starting materials.
The compounds of formula (I) may exist in crystalline or amorphous form. Furthermore, some of the crystalline forms of the compounds of formula (I) may exist as polymorphs, which are included within the scope of the present invention. Polymorphic forms of compounds of formula (I) may be characterized and differentiated using a number of conventional analytical techniques, including, but not limited to, X-ray powder diffraction (XRPD) patterns, infrared (IR) spectra, Raman spectra, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and solid state nuclear magnetic resonance (ssNMR).
In case the compounds according to formula (I) contain one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Compounds of the formula (I) which contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples for suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the compounds of the formula (I) simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts according to the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
Throughout the invention, the term “pharmaceutically acceptable” means that the corresponding compound, carrier or molecule is suitable for administration to humans. Preferably, this term means approved by a regulatory agency such as the EMEA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.
The present invention furthermore includes all solvates of the compounds according to the invention.
According to the present invention “JAK” comprises all members of the JAK family (e.g. JAK1, JAK2, JAK3, and TYK2).
According to the present invention, the expression “JAK1” or “JAK1 kinase” means “Janus kinase 1”. The human gene encoding JAK1 is located on chromosome 1p31.3.
According to the present invention, the expression “JAK2” or “JAK2 kinase” means “Janus kinase 2”. The human gene encoding JAK2 is located on chromosome 9p24.
According to the present invention, the expression “JAK3” or “JAK3 kinase” means “Janus kinase 3”. The gene encoding JAK3 is located on human chromosome 19p13.1 and it is predominantly in hematopoietic cells. JAK3 is a cytoplasmic protein tyrosine kinase that associates with the gamma-chain of the interleukin 2 (IL-2) receptor. This chain also serves as a component for the receptors of several lymphotrophic cytokines, including interleukins IL-4, IL-7, IL-9, IL-15 and IL-21 (Schindler et al., 2007. J. Biol. Chem. 282(28):20059-63). JAK3 plays a key role in the response of immune cells to cytokines, especially in mast cells, lymphocytes and macrophages Inhibition of JAK3 has shown beneficial effects in the prevention of transplant rejection (Changelian et al., 2003, Science 302(5646):875-888).
Moreover, according to the present invention, the expression “JAK3” or “JAK3 kinase” includes mutant forms of JAK3, preferably JAK3 mutants found in acute megakaryoblastic leukemia (AMKL) patients. More preferred, these mutants are single amino acid mutations. Activating JAK3 mutations were observed in acute megakaryoblastic leukemia (AMKL) patients (Walters et al., 2006. Cancer Cell 10(1):65-75). Therefore, in a preferred embodiment, the expression “JAK” also includes a JAK3 protein having a V7221 or P132T mutation.
According to the present invention, the expression “TYK2” or “TYK2 kinase” means “Protein-Tyrosine kinase 2”. The JAK3 and TYK2 genes are clustered on chromosome 19p13.1 and 19p13.2, respectively.
As shown in the examples, compounds of the invention were tested for their selectivity for JAK1 or JAK3 or Tyk2 over JAK2 kinases. As shown, all tested compounds bind JAK1 or JAK3 or Tyk2 more selectively than JAK2 (see table 5 below). It is clear that many of the side effects noted during clinical trials of JAK family inhibitors are mediated via inhibition of JAK2 (Fleischmann et al./Kremer et al., ACR presentation (2009)). Thus there is a need for JAK family inhibitors with an improved selectivity over JAK2.
Consequently, the compounds of the present invention are considered to be useful for the prevention or treatment of diseases and disorders associated with JAK, for example immunological, inflammatory, autoimmune, or allergic disorders, transplant rejection, Graft-versus-Host-Disease or proliferative diseases such as cancer.
In a preferred embodiment, the compounds of the present invention are selective JAK3 inhibitors.
Equally preferred are dual JAK1/JAK3 inhibitors.
Equally preferred are selective JAK1 inhibitors.
Equally preferred are selective Tyk2 inhibitors.
Equally preferred are dual JAK1/Tyk2 inhibitors.
Equally preferred are JAK1/Tyk2/JAK3 inhibitors with selectivity over JAK2.
Accordingly diseases and disorders associated with JAK, especially those mentioned herein, are diseases and disorders associated with JAK3, JAK1/JAK3, JAK1, Tyk2, JAK1/Tyk2 or JAK1/Tyk2/JAK3.
The compounds of the present invention may be further characterized by determining whether they have an effect on JAK3, for example on its kinase activity (Changelian et al., 2003, Science 302(5646):875-888 and online supplement; Yang et al., 2007. Bioorg. Med. Chem. Letters 17(2): 326-331).
Briefly, JAK3 kinase activity can be measured using a recombinant GST-JAK3 fusion protein comprising the catalytic domain (JH1 catalytic domain). JAK3 kinase activity is measured by ELISA as follows: Plates are coated overnight with a random L-glutamic acid and tyrosine co-polymer (4:1; 100 μg/ml) as a substrate. The plates are washed and recombinant JAK3 JH1:GST protein (100 ng/well) with or without inhibitors is incubated at room temperature for 30 minutes. The a HPR-conjugated PY20 anti-phosphotyrosine antibody (ICN) is added and developed by TMB (3,3′,5,5′-tetramethylbenzidine) (Changelian et al., 2003, Science 302(5646):875-888 and online supplement).
A cell-based assays (TF-1 cell proliferation) was described to assess the inhibitory activity of small molecule drugs toward JAK2 or JAK3-dependent signal transduction (Chen et al., 2006. Bioorg. Med. Chem. Letters 16(21): 5633-5638).
The present invention provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt or isotopic derivative thereof as active ingredient together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.
“Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered orally. Saline and aqueous dextrose are preferred carriers when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid carriers for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.
A pharmaceutical composition of the present invention may comprise one or more additional compounds as active ingredients like one or more compounds of formula (I) not being the first compound in the composition or other JAK inhibitors. Further bioactive compounds may be steroids, leukotriene antagonists, cyclosporine or rapamycin.
The compounds of the present invention or pharmaceutically acceptable salt(s) or isotopic derivative(s) thereof and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, this may occur separately or sequentially in any order. When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation. When formulated separately they may be provided in any convenient formulation, conveniently in such manner as are known for such compounds in the art.
It is further included within the present invention that the compound of formula (I), or a pharmaceutically acceptable salt or isotopic derivative thereof, or a pharmaceutical composition comprising a compound of formula (I) is administered in combination with another drug or pharmaceutically active agent and/or that the pharmaceutical composition of the invention further comprises such a drug or pharmaceutically active agent.
In this context, the term “drug or pharmaceutically active agent” includes a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
“Combined” or “in combination” or “combination” should be understood as a functional coadministration, wherein some or all compounds may be administered separately, in different formulations, different modes of administration (for example subcutaneous, intravenous or oral) and different times of administration. The individual compounds of such combinations may be administered either sequentially in separate pharmaceutical compositions as well as simultaneously in combined pharmaceutical compositions.
For example, in rheumatoid arthritis therapy, combination with other chemotherapeutic or antibody agents is envisaged. Suitable examples of pharmaceutically active agents which may be employed in combination with the compounds of the present invention and their salts for rheumatoid arthritis therapy include immunosuppressants such as amtolmetin guacil, mizoribine and rimexolone; anti-TNFα agents such as etanercept, infliximab, Adalimumab, Anakinra, Abatacept, Rituximab; tyrosine kinase inhibitors such as leflunomide; kallikrein antagonists such as subreum; interleukin 11 agonists such as oprelvekin; interferon beta 1 agonists; hyaluronic acid agonists such as NRD-101 (Aventis); interleukin 1 receptor antagonists such as anakinra; CD8 antagonists such as amiprilose hydrochloride; beta amyloid precursor protein antagonists such as reumacon; matrix metalloprotease inhibitors such as cipemastat and other disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate, sulphasalazine, cyclosporin A, hydroxychloroquine, auranofin, aurothioglucose, gold sodium thiomalate and penicillamine.
In particular, the treatment defined herein may be applied as a sole therapy or may involve, in addition to the compounds of the invention, conventional surgery or radiotherapy or chemotherapy. Accordingly, the compounds of the invention can also be used in combination with existing therapeutic agents for the treatment proliferative diseases such as cancer. Suitable agents to be used in combination include:
(i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like paclitaxel and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecins);
(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5α-reductase such as finasteride;
(iii) anti-invasion agents (for example c-Src kinase family inhibitors like 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxy-quinazoline (AZD0530) and N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825), and metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
(iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [Herceptin™] and the anti-erbB1 antibody cetuximab [C225]); such inhibitors also include, for example, tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD 1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI-1033) and erbB2 tyrosine kinase inhibitors such as lapatinib), inhibitors of the hepatocyte growth factor family, inhibitors of the platelet-derived growth factor family such as imatinib, inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib (BAY 43-9006)) and inhibitors of cell signalling through MEK and/or Akt kinases;
(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™) and VEGF receptor tyrosine kinase inhibitors such as 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (ZD6474; Example 2 within WO 01/32651), 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00/47212), vatalanib (PTK787; WO 98/35985) and SU11248 (sunitinib; WO 01/60814), and compounds that work by other mechanisms (for example linomide, inhibitors of integrin αvβ3 function and angio statin);
(vi) vascular damaging agents such as combretastatin A4 and compounds disclosed in International Patent Application WO 99/02166;
(vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense agent;
(viii) gene therapy approaches, including approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and (ix) immunotherapeutic approaches, including ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
Further combination treatments are described in WO-A 2009/008992 and WO-A 2007/107318), incorporated herein by reference.
Accordingly, the individual compounds of such combinations may be administered either sequentially in separate pharmaceutical compositions as well as simultaneously in combined pharmaceutical compositions.
The pharmaceutical compositions of the present invention include compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
In practical use, the compounds of formula (I) can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally, for example, as liquid drops or spray.
The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as fatty oil.
Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
Compounds of formula (I) may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Preferably compounds of formula (I) are administered orally.
The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
A therapeutically effective amount of a compound of the present invention will normally depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration. However, an effective amount of a compound of formula (I) for the treatment of an inflammatory disease, for example rheumatoid arthritis (RA), will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day. Thus, for a 70 kg adult mammal, the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a pharmaceutically acceptable salt, prodrug or metabolite thereof, may be determined as a proportion of the effective amount of the compound of formula (I) per se. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.
As used herein, the term “effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
Furthermore, the term “therapeutically effective amount” means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.
Another aspect of the present invention is a compound of the present invention or a pharmaceutically acceptable salt or isotopic derivative thereof for use as a medicament.
Another aspect of the present invention is a compound of the present invention or a pharmaceutically acceptable salt or isotopic derivative thereof for use in a method of treating or preventing a disease or disorder associated with JAK.
In the context of the present invention, a disease or disorder associated with JAK is defined as a disease or disorder where JAK is involved.
In a preferred embodiment, wherein the diseases or disorder is associated with JAK is an immunological, inflammatory, autoimmune, or allergic disorder or disease of a transplant rejection or a Graft-versus host disease.
Consequently, another aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use in a method of treating or preventing an immunological, inflammatory, autoimmune, or allergic disorder or disease of a transplant rejection or a Graft-versus host disease.
Inflammation of tissues and organs occurs in a wide range of disorders and diseases and in certain variations, results from activation of the cytokine family of receptors. Exemplary inflammatory disorders associated with activation of JAK include, in a non-limiting manner, skin inflammation due radiation exposure, asthma, allergic inflammation and chronic inflammation.
According to the present invention, an autoimmune disease is a disease which is at least partially provoked by an immune reaction of the body against own components, for example proteins, lipids or DNA. Examples of organ-specific autoimmune disorders are insulin-dependent diabetes (Type I) which affects the pancreas, Hashimoto's thyroiditis and Graves' disease which affect the thyroid gland, pernicious anemia which affects the stomach, Cushing's disease and Addison's disease which affect the adrenal glands, chronic active hepatitis which affects the liver; polycystic ovary syndrome (PCOS), celiac disease, psoriasis, inflammatory bowel disease (IBD) and ankylosing spondylitis. Examples of non-organ-specific autoimmune disorders are rheumatoid arthritis, multiple sclerosis, systemic lupus and myasthenia gravis.
Type I diabetes ensues from the selective aggression of autoreactive T-cells against insulin secreting beta-cells of the islets of Langerhans. Targeting JAK3 in this disease is based on the observation that multiple cytokines that signal through the JAK pathway are known to participate in the T-cell mediated autoimmune destruction of beta-cells. Indeed, a JAK3 inhibitor, JANEX-1 was shown to prevent spontaneous autoimmune diabetes development in the NOD mouse model of tune I diabetes.
In a preferred embodiment, the autoimmune disease is selected from the group consisting of rheumatoid arthritis (RA), inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis), psoriasis, systemic lupus erythematosus (SLE), and multiple sclerosis (MS).
Rheumatoid arthritis (RA) is a chronic progressive, debilitating inflammatory disease that affects approximately 1% of the world's population. RA is a symmetric polyarticular arthritis that primarily affects the small joints of the hands and feet. In addition to inflammation in the synovium, the joint lining, the aggressive front of tissue called pannus invades and destroys local articular structures (Firestein 2003, Nature 423:356-361).
Inflammatory bowel disease (IBD) is characterized by a chronic relapsing intestinal inflammation. IBD is subdivided into Crohn's disease and ulcerative colitis phenotypes. Crohn disease involves most frequently the terminal ileum and colon, is transmural and discontinuous. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers. In approximately 10% of cases confined to the rectum and colon, definitive classification of Crohn's disease or ulcerative colitis cannot be made and are designated ‘indeterminate colitis.’ Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Neutrophil-induced injuries may be prevented by the use of neutrophils migration inhibitors (Asakura et al., 2007, World J Gastroenterol. 13(15):2145-9).
Psoriasis is a chronic inflammatory dermatosis that affects approximately 2% of the population. It is characterized by red, scaly skin patches that are usually found on the scalp, elbows, and knees, and may be associated with severe arthritis. The lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis (Schön et al., 2005, New Engl. J. Med. 352:1899-1912).
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease generated by T cell-mediated B-cell activation, which results in glomerulonephritis and renal failure. Human SLE is characterized at early stages by the expansion of long-lasting autoreactive CD4+ memory cells (D'Cruz et al., 2007, Lancet 369(9561):587-596).
Multiple sclerosis (MS) is an inflammatory and demyelating neurological disease. It has bee considered as an autoimmune disorder mediated by CD4+ type 1 T helper cells, but recent studies indicated a role of other immune cells (Hemmer et al., 2002, Nat. Rev. Neuroscience 3, 291-301).
Mast cells express JAK3 and JAK3 is a key regulator of the IgE mediated mast cell responses including the release of inflammatory mediators. JAK3 was shown to be a valid target in the treatment of mast cell mediated allergic reaction. Allergic disorders associated with mast cell activation include Type I immediate hypersensitivity reactions such as allergic rhinitis (hay fever), allergic urticaria (hives), angioedema, allergic asthma and anaphylaxis, for example anaphylactic shock. These disorders may be treated or prevented by inhibition of JAK3 activity, for example, by administration of a JAK3 inhibitor according to the present invention.
Transplant rejection (allograft transplant rejection) includes, without limitation, acute and chronic allograft rejection following for example transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea. It is known that T cells play a central role in the specific immune response of allograft rejection. Hyperacute, acute and chronic organ transplant rejection may be treated. Hyperacute rejection occurs within minutes of transplantation. Acute rejection generally occurs within six to twelve months of the transplant. Hyperacute and acute rejections are typically reversible where treated with immunosuppressant agents. Chronic rejection, characterized by gradual loss of organ function, is an ongoing concern for transplant recipients because it can occur anytime after transplantation.
Graft-versus-host disease (GVDH) is a major complication in allogeneic bone marrow transplantation (BMT). GVDH is caused by donor T cells that recognize and react to recipient differences in the histocompatibility complex system, resulting in significant morbidity and mortality. JAK3 plays a key role in the induction of GVHD and treatment with a JAK3 inhibitor, JANEX-1, was shown to attenuate the severity of GVHD (reviewed in Cetkovic-Cvrlje and Ucken, 2004).
In a preferred embodiment, the inflammatory disease is an eye disease.
Dry eye syndrome (DES, also known as keratoconjunctivitis sicca) is one of the most common problems treated by eye physicians. Sometimes DES is referred to as dysfunctional tear syndrome (Jackson, 2009. Canadian Journal Ophthalmology 44(4), 385-394). DES affects up to 10% of the population between the ages of 20 to 45 years, with this percentage increasing with age. Although a wide variety of artificial tear products are available, these products provide only transitory relief of symptoms. As such, there is a need for agents, compositions and therapeutic methods to treat dry eye.
As used herein, “dry eye disorder” is intended to encompass the disease states summarized in a recent official report of the Dry Eye Workshop (DEWS), which defined dry eye as “a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolality of the tear film and inflammation of the ocular surface.” (Lemp, 2007. “The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop”, The Ocular Surface, 5(2), 75-92). Dry eye is also sometimes referred to as keratoconjunctivitis sicca. In some embodiments, the treatment of the dry eye disorder involves ameliorating a particular symptom of dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface.
Uveitis is the most common form of intraocular inflammation and remains a significant cause of visual loss. Current treatments for uveitis employs systemic medications that have severe side effects and are globally immunosuppressive. Clinically, chronic progressive or relapsing forms of non-infectious uveitis are treated with topical and/or systemic corticosteroids. In addition, macrolides such as cyclosporine and rapamycin are used, and in some cases cytotoxic agents such as cyclophosphamide and chlorambucil, and antimetabolites such as azathioprine, methotrexate, and leflunomide (Srivastava et al., 2010. Uveitis: Mechanisms and recent advances in therapy. Clinica Chimica Acta, doi:10.1016/j.cca.2010.04.017).
Further eye diseases, combination treatments and route of administration are described for example in WO-A 2010/039939, which is hereby incorporated herein by reference.
In a further preferred embodiment, the disease or disorder associated with JAK is a proliferative disease, especially cancer.
Diseases and disorders associated especially with JAK are proliferative disorders or diseases, especially cancer.
Therefore, another aspect of the present invention is a compound or a pharmaceutically acceptable salt or isotopic derivative thereof of the present invention for use in a method of treating or preventing a proliferative disease, especially cancer.
Cancer comprises a group of diseases characterized by uncontrolled growth and spread of abnormal cells. All types of cancers generally involve some abnormality in the control of cell growth, division and survival, resulting in the malignant growth of cells. Key factors contributing to said malignant growth of cells are independence from growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis, and genome instability (Hanahan and Weinberg, 2000. The Hallmarks of Cancer. Cell 100, 57-70).
Typically, cancers are classified as hematological cancers (for example leukemias and lymphomas) and solid cancers such as sarcomas and carcinomas (for example cancers of the brain, breast, lung, colon, stomach, liver, pancreas, prostate, ovary).
The JAK inhibitors of the present invention may also useful in treating certain malignancies, including skin cancer and hematological malignancy such as lymphomas and leukemias.
Especially cancers in which the JAK-STAT signal transduction pathway is activated, for example due to activation of JAK3 are expected to respond to treatment with JAK3 inhibitors.
Examples of cancers harboring JAK3 mutations are acute megakaryoblastic leukemia (AMKL) (Walters et al., 2006. Cancer Cell 10(1):65-75) and breast cancer (Jeong et al., 2008. Clin. Cancer Res. 14, 3716-3721).
Proliferative diseases or disorders comprise a group of diseases characterized by increased cell multiplication as observed in myeloproliferative disorders (MPD) such as polycythemia vera (PV).
Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt or isotopic derivative thereof for the manufacture of a medicament for the treatment or prophylaxis of diseases and disorders associated with JAK.
Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt or isotopic derivative thereof for the manufacture of a medicament for treating or preventing an immunological, inflammatory, autoimmune, or allergic disorder or disease or a transplant rejection or a Graft-versus host disease.
Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt or isotopic derivative thereof for the manufacture of a medicament for treating or preventing a proliferative disease, especially cancer.
In the context of these uses of the invention, diseases and disorders associated with JAK are as defined above.
Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need thereof one or more conditions selected from the group consisting of diseases and disorders associated with JAK, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to present invention or a pharmaceutically acceptable salt or isotopic derivative thereof.
Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need thereof one or more conditions selected from the group consisting of an immunological, inflammatory, autoimmune, or allergic disorder or disease or a transplant rejection or a Graft-versus host disease, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to present invention or a pharmaceutically acceptable salt or isotopic derivative thereof.
Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need thereof a proliferative disease, especially cancer, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to present invention or a pharmaceutically acceptable salt or isotopic derivative thereof.
In the context of these methods of the invention, diseases and disorders associated with JAK are as defined above.
As used herein, the term “treating” or “treatment” is intended to refer to all processes, wherein there may be a slowing, interrupting, arresting, or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.
All embodiments discussed above with respect to the pharmaceutical composition of the invention also apply to the above mentioned first or second medical uses or methods of the invention.
General methods for the preparation of compounds of the present invention are known in the art, e.g. from WO 2008/129380 A. In the following experimental section preparation methods are described which also can be used in analogues methods using methods known to the skilled person in the art, especially methods for protecting reactive functional groups or activating functional groups.
It will be appreciated that novel intermediates described herein form another embodiment of the present invention.
LCMS (methods A and B) was carried out on an Agilent 1100 using a Gemini C18, 3×30 mm, 3 micron. Column flow was 1.2 mL/min and solvents used were water and acetonitrile (0.1% formic acid—low pH, 0.1% ammonia—high pH) with an injection volume of 3 μL. Wavelengths were 254 and 210 nm. LCMS method C was carried out on a Waters uPLC-SQD. Photodiode array detection was between 210 and 400 nm.
Column: Phenomenex Gemini-C18, 3×30 mm, 3 microns. Flow rate: 1.2 mL/min
Column: Phenomenex Gemini-C18, 4.6×150 mm, 5 microns. Flow rate 1.0 mL/min
Column: Waters Acquity UPLC BEH C18, 2.1×30 mm, 1.7 microns. Flow rate 0.5 mL/min
1,3,5 trichloropyrimidine (600 mgs) was dissolved in ethanol (5 ml) and diisopropylamine (624 uls) was added. The reaction was cooled to 0° C. and (R)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate (654 mgs) was added. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was diluted with 1M hydrochloric acid to pH4 and extracted with dichloromethane (3×10 ml). The extracts were filtered through a hydrophobic frit and concentrated under reduced pressure to give (R)-tert-butyl 2-(((2,5-dichloropyrimidin-4-yl)amino)methyl)pyrrolidine-1-carboxylate.
Retention Time Method C 1.27 mins, M+H+=347/349
Was prepared following the same method but with (S)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate
Retention Time Method C 1.27 mins, M+H+=347/349
Was prepared following the same method but with tert-butyl 3-(aminomethyl)azetidine-1-carboxylate
Retention Time Method C 1.14 mins, M+H+=333/335
Was prepared following the same method but with (R)-tert-butyl 3-(aminomethyl)pyrrolidine-1-carboxylate
Retention Time Method C 1.18 mins, M+H+=347/349
Was prepared following the same method but with (S)-tert-butyl 3-(aminomethyl)pyrrolidine-1-carboxylate
Retention Time Method C 1.18 mins, M+H+=347/349
Was prepared following the same method but with (S)-tert-butyl 2-(aminomethyl)piperidine-1-carboxylate
Retention Time Method C 1.26 mins, M+H+=361/363
Was prepared following the same method but with (R)-tert-butyl 2-(aminomethyl)piperidine-1-carboxylate
Retention Time Method C 1.26 mins, M+H+=361/363
Was prepared following the same method but with (R)-tert-butyl 3-(aminomethyl)piperidine-1-carboxylate
Retention Time Method C 1.26 mins, M+H+=361/363
Was prepared following the same method but with (S)-tert-butyl 3-(aminomethyl)piperidine-1-carboxylate
Retention Time Method C 1.26 mins, M+H+=361/363
Intermediate 1 (500 mgs) was dissolved in 4M hydrogen chloride in dioxan (5 ml) and allowed to stand at room temperature for 2 hours when a thick precipitate had formed. The reaction was diluted with ethyl acetate (5 ml) and the solvents decanted. The residue was triturated with ethyl acetate (2×5 m) then dried in vacuo to give R-2,5-dichloro-N-(pyrrolidin-2-ylmethyl)pyrimidin-4-amine as the HCl salt
Retention Time Method C 0.67 mins, M+H+=247/249
Intermediate 11 (S)-2,5-dichloro-N-(pyrrolidin-2-ylmethyl)pyrimidin-4-amine was prepared following the same method but with Intermediate 2
Retention Time Method C 0.67 mins, M+H+=247/249
Was prepared following the same method but with Intermediate 3
Retention Time Method C 0.65 mins, M+H+=233/235
Was prepared following the same method but with Intermediate 4
Retention Time Method C 0.69 mins, M+H+=247/249
Was prepared following the same method but with Intermediate 5
Retention Time Method C 0.68 mins, M+H+=247/249
Was prepared following the same method but with Intermediate 6
Retention Time Method C 0.69 mins, M+H+=261/263
Was prepared following the same method but with Intermediate 7
Retention Time Method C 0.69 mins, M+H+=261/263
Was prepared following the same method but with Intermediate 8
Retention Time Method C 1.26 mins, M+H+=361/363
Was prepared following the same method but with Intermediate 9
Retention Time Method C 1.26 mins, M+H+=361/363
Was prepared according to the method of intermediate 1 using (tetrahydro-2H-pyran-4-yl)methanamine as the nucleophile
Retention Time Method A 2.18 mins, M+H+=261/3
Was prepared according to the method of intermediate 1 using cyclohexylmethanamine as the nucleophile
Retention Time Method A 3.05 mins, M+H+=259/61
Intermediate 1 (773 mg) and 1-Methyl-1H-pyrazolo-4-ylamine (2.45 mmol) were dissolved in isopropanol (5 mL) and 4M HCl in Dioxane (3.57 mmol) added. The reaction was heated at 120° C. for 30 min in a microwave. The reaction mixture was filtered and the filter cake washed with isopropanol and diethyl ether.
Retention Time Method B 7.30 mins, M+H+=308
Was prepared following the same method but with intermediate 2 and 1-Methyl-1H-pyrazolo-4-ylamine
Retention Time Method A 2.09 mins, M+H+=308
Was prepared following the same method but with intermediate 4 and 1-Methyl-1H-pyrazolo-4-ylamine
2,4-dichloro-5-fluoropyrimidine (500 mg, 3.01 mmol) and (R)-(2-aminomethyl)-1-boc-pyrrolidine (3.31 mmol) were dissolved in isopropanol and DIPEA added. The reaction was stirred at 60° C. for 2 h. The mixture was diluted with dichloromethane, washed with water, dried using a hydrophobic frit then concentrated in vacuo to afford the title compound as an orange gum.
Retention Time Method A 2.63 mins, M+H+=331
Was prepared following the same method but with (S)-(2-aminomethyl)-1-boc-pyrrolidine and 2,4-dichloro-5-fluoropyrimidine
Retention Time Method A 2.63 min, M+H+=331
Was prepared following the same method but with 2,4-dichloro-5-methylpyrimidine and (R)-(2-aminomethyl)-1-boc-pyrrolidine
Retention Time Method A 2.63 mins, M+H+=327
Was prepared following the same method but with 2,4-dichloro-5-methylpyrimidine and (S)-(2-aminomethyl)-1-boc-pyrrolidine
Retention time Method A 2.62 mins, M+H+=327
Intermediate 28 5-(((2,5-dichloropyrimidin-4-yl)amino)methyl)-1-methylpyrrolidin-2-one was prepared using the same method but with 2,4,5-trichloro-pyrimidine and 5-(aminomethyl)-1-methylpyrrolidin-2-one
Retention time Method A 1.80 mins, M+H+=275
Intermediate 29 (R)-tert-butyl 2-(((2-chloropyrimidin-4-yl)amino)methyl)pyrrolidine-1-carboxylate was prepared according to the method of intermediate 24 but using 2,4-dichloropyrimidine. The product was purified by flash column chromatography on silica eluting with ethyl acetate and 40/60 petroleum ether.
Retention time Method A 2.50 mins, M+H+=313
Intermediate 30 (R)—N-isopropyl-2-(4-((4-((pyrrolidin-2-ylmethyl)amino)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)acetamide was prepared according to the method of intermediate 21 using intermediate 29 and 2-(4-amino-1H-pyrazol-1-yl)-N-isopropylacetamide.
Retention time Method A 2.05 mins, M+H+=339
Intermediate 31 (R)-2,5-dichloro-N-((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)pyrimidin-4-amine was prepared from intermediate 13. Intermediate 13 (100 mg) was stirred overnight in dichloromethane with triethylamine (100 ul) and methanesulfonylchloride (100 ul). The reaction was then diluted with further dichloromethane and washed with 1M citric acid and water. The phases were separated and the organic phase was concentrated under reduced pressure.
Retention time Method A 2.09 mins, M+H+=325
Intermediate 32 tert-butyl 3-(((2,5-dichloropyrimidin-4-yl)amino)methyl)morpholine-4-carboxylate was prepared in a similar manner to intermediate 1 using tert-butyl 3-(amino methyl)morpholine-4-carboxylate.
Retention time Method A 2.52 mins, M+H+=363
Intermediate 33 5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)-N4-(morpholin-3-ylmethyl)pyrimidine-2,4-diamine was prepared in a similar manner to intermediate 21 from intermediate 32.
Retention time Method A 1.74 mins, M+H+=324
Intermediate 34 (2S,4S)-tert-butyl 2-(((2,5-dichloropyrimidin-4-yl)amino)methyl)-4-fluoropyrrolidine-1-carboxylate was prepared in a similar manner to intermediate 1 using (2S,4S)-tert-butyl 2-(aminomethyl)-4-fluoropyrrolidine-1-carboxylate
Retention time Method A 2.79 mins, M+H+=365
Intermediate 35 5-chloro-N4-(((2S,4S)-4-fluoropyrrolidin-2-yl)methyl)-N2-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine was prepared in a similar manner to intermediate 21 from intermediate 34
Retention time Method A 1.87 mins, M+H+=362
Intermediate 36 (R)—N2-(1-methyl-1H-pyrazol-4-yl)-N4-(pyrrolidin-2-ylmethyl)pyrimidine-2,4-diamine was prepared from intermediate 29 and 1-methyl-1H-pyrazol-4-amine using the method of intermediate 21
Retention time Method A 1.91 mins, M+H+=274
Intermediate 37 (2S,4S)-tert-butyl 2-(((2-chloro-5-methylpyrimidin-4-yl)amino)methyl)-4-fluoropyrrolidine-1-carboxylate was prepared in a similar manner to intermediate 1 using (2S,4S)-tert-butyl 2-(aminomethyl)-4-fluoropyrrolidine-1-carboxylate and 2,4-dichloro-5-methylpyrimidine
Retention time Method A 2.63 mins, M+H+=345
Intermediate 38 N4-(((2S,4S)-4-fluoropyrrolidin-2-yl)methyl)-5-methyl-N2-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine was prepared from intermediate 37 in a similar manner to intermediate 21
Retention time Method A 1.71 mins, M+H+=306
Intermediate 39 (R)-tert-butyl 3-(((2-chloro-5-methylpyrimidin-4-yl)amino)methyl)pyrrolidine-1-carboxylate was prepared from (R)-tert-butyl 3-(aminomethyl)pyrrolidine-1-carboxylate and 2,4-dichloro-5-methylpyrimidine in a similar manner to intermediate 1
Retention time Method A 2.33 mins, M+H+=327
Intermediate 40 (R)-5-methyl-N2-(1-methyl-1H-pyrazol-4-yl)-N4-(pyrrolidin-3-ylmethyl)pyrimidine-2,4-diamine was prepared from intermediate 39 and 1-methyl-1H-pyrazol-4-amine in a similar manner to intermediate 21
Retention time Method A 1.87 mins, M+H+=288
Intermediate 41 (R)—N2-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-5-methyl-N4-(pyrrolidin-2-ylmethyl)pyrimidine-2,4-diamine was prepared from (R)-tert-butyl 2-(((2-chloro-5-methylpyrimidin-4-yl)amino)methyl)pyrrolidine-1-carboxylate and 1-(2,2-difluoroethyl)-1H-pyrazol-4-amine in a similar manner to intermediate 21.
(R)-tert-butyl 2-(((2-chloro-5-methylpyrimidin-4-yl)amino)methyl)pyrrolidine-1-carboxylate was prepared from (R)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate and 2,4-dichloro-5-methylpyrimidine in a similar manner to intermediate 1
Retention time Method A 2.81 mins, M+H+=335
Intermediate 42 (2S,4S)-tert-butyl 2-(((2-chloro-5-methylpyrimidin-4-yl)amino)methyl)-4-fluoropyrrolidine-1-carboxylate was prepared from (2S,4S)-tert-butyl 2-(aminomethyl)-4-fluoropyrrolidine-1-carboxylate and 2,4-dichloro-5-methylpyrimidine in a similar manner to intermediate 1
Retention time Method A 2.63 mins, M+H+=345
Intermediate 43 N2-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-N4-(((2S,4S)-4-fluoropyrrolidin-2-yl)methyl)-5-methylpyrimidine-2,4-diamine was prepared from intermediate 42 and 1-(2,2-difluoroethyl)-1H-pyrazol-4-amine in a similar manner to intermediate 21.
Retention time Method A 1.89 mins, M+H+=356
Intermediate 44 (S)-tert-butyl 2-(((2-chloro-5-methylpyrimidin-4-yl)amino)methyl)pyrrolidine-1-carboxylate was prepared from (S)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate and 2,4-dichloro-5-methylpyrimidine in a similar manner to intermediate 1
Retention time Method A 2.77 mins, M+H+=327
Intermediate 45 (S)—N2-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-5-methyl-N4-(pyrrolidin-2-ylmethyl)pyrimidine-2,4-diamine was prepared from intermediate 44 and 1-(2,2-difluoroethyl)-1H-pyrazol-4-amine in a similar manner to intermediate 21.
Retention time Method A 2.09 mins, M+H+=338
Intermediate 46 (R)-tert-butyl 3-(((2-chloro-5-methylpyrimidin-4-yl)amino)methyl)pyrrolidine-1-carboxylate was prepared from (R)-tert-butyl 3-(aminomethyl)pyrrolidine-1-carboxylate and 2,4-dichloro-5-methylpyrimidine in a similar manner to intermediate 1
Retention time Method A 2.54 mins, M+H+=327
Intermediate 47 (R)—N2-(1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)-5-methyl-N4-(pyrrolidin-3-ylmethyl)pyrimidine-2,4-diamine was prepared from intermediate 46 and 1-(2,2-difluoroethyl)-1H-pyrazol-4-amine in a similar manner to intermediate 21.
Retention time Method A 2.13 mins, M+H+=338
Intermediate 48 5-chloro-N4-(((2S,4S)-4-fluoropyrrolidin-2-yl)methyl)-N2-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine was prepared from intermediate 34 and 1-methyl-1H-pyrazol-4-amine in a similar method to intermediate 21
Retention time Method A 1.84 mins, M+H+=326
Intermediate 49 tert-butyl 3-(((2,5-dichloropyrimidin-4-yl)amino)methyl)piperidine-1-carboxylate was prepared from tert-butyl 3-(aminomethyl)piperidine-1-carboxylate and 2,4,5-trichloropyrimidine in a manner similar to intermediate 1
Retention time Method A 1.20 mins, M+H+=361
Intermediate 50 5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)-N4-(piperidin-3-ylmethyl)pyrimidine-2,4-diamine was prepared as a racemate in a similar manner to intermediate 21 from intermediate 49 and 1-methyl-1H-pyrazol-4-amine
Retention time Method A 0.92 mins, M+H+=322
Intermediate 51 (R)-5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)-N4-(piperidin-3-ylmethyl)pyrimidine-2,4-diamine was made in a similar manner to intermediate 50 using (R)-tert-butyl 3-(aminomethyl)piperidine-1-carboxylate.
Retention time Method A 0.92 mins, M+H+=322
Intermediate 52 (S)-5-chloro-N2-(1-methyl-1H-pyrazol-4-yl)-N4-(piperidin-3-ylmethyl)pyrimidine-2,4-diamine was made in a similar manner to intermediate 50 using (S)-tert-butyl 3-(aminomethyl)piperidine-1-carboxylate.
Retention time Method A 0.94 mins, M+H+=322
Intermediate 10 (120 mgs) was dissolved in dichloromethane (5 ml) and di-isopropylethylamine (180 ul) was added. The reaction was stirred and acetyl chloride (57 ul) was added. The reaction was stirred for 2 hrs and then 1M hydrochloric acid (2 ml) was added. The phases were separated on a hydrophobic frit and the organic layer concentrated under reduced pressure.
The residue was dissolved in isopropanol (1 mL) and 1-methyl-1H-pyrazol-4-amine (48 mg) together with a drop of 4M hydrogen chloride in dioxan were added. The reaction was heated at 140° C. for 45 minutes in a microwave. Solvents were removed under reduced pressure and the residue was purified on reverse phase silica eluting with a gradient of 100% 0.1% ammonia in water to 50% 0.1% ammonia in water and 50% 0.1% ammonia in acetonitrile over 15 minutes.
Retention Time Method C 0.73 mins, M+H+=350/2
Retention Time Method C 0.70 mins, M+H+=380/2
Intermediate 10 (121 mgs) was dissolved in dichloromethane (5 ml) and di-isopropylethylamine (180 ul) was added. The reaction was stirred and acroyl chloride (44 ul) was added. The reaction was stirred for 2 hrs and then 1M hydrochloric acid (2 ml) was added. The phases were separated on a hydrophobic frit and the organic layer concentrated under reduced pressure.
The residue was dissolved in isopropanol (1 mL) and 1-methyl-1H-pyrazol-4-amine (48 mg) together with a drop of 4M hydrogen chloride in dioxan were added. The reaction was heated at 140° C. for 45 minutes in a microwave. Solvents were removed under reduced pressure and the residue was purified on reverse phase silica eluting with a gradient of 100% 0.1% ammonia in water to 50% 0.1% ammonia in water and 50% 0.1% ammonia in acetonitrile over 15 minutes.
Retention Time Method C 0.74 mins, M+H+=362/4
Retention Time Method C 0.71 mins, M+H+=392/4
Intermediate 10 (113 mgs) was dissolved in dichloromethane (5 ml) and di-isopropylethylamine (180 ul) was added. The reaction was stirred and methanesulfonyl chloride (39 ul) was added. The reaction was stirred for 2 hrs and then 1M hydrochloric acid (2 ml) was added. The phases were separated on a hydrophobic frit and the organic layer concentrated under reduced pressure.
The residue was dissolved in isopropanol (1 mL) and 1-methyl-1H-pyrazol-4-amine (48 mg) together with a drop of 4M hydrogen chloride in dioxan were added. The reaction was heated at 140° C. for 45 minutes in a microwave. Solvents were removed under reduced pressure and the residue was purified on reverse phase silica eluting with a gradient of 100% 0.1% ammonia in water to 50% 0.1% ammonia in water and 50% 0.1% ammonia in acetonitrile over 15 minutes.
Retention Time Method C 0.74 mins, M+H+=386/8
Retention Time Method C 0.70 mins, M+H+=416/8
Intermediate 10 (51 mgs) was dissolved in dichloromethane (5 ml) and di-isopropylethylamine (180 ul) was added. The reaction was stirred and 2-chloroethanesulfonyl chloride (24 ul) was added. The reaction was stirred for 2 hrs and then 1M hydrochloric acid (2 ml) was added. The phases were separated on a hydrophobic frit and the organic layer concentrated under reduced pressure.
The residue was dissolved in isopropanol (1 mL) and 1-methyl-1H-pyrazol-4-amine (26 mg) together with a drop of 4M hydrogen chloride in dioxan were added. The reaction was heated at 140° C. for 45 minutes in a microwave. Solvents were removed under reduced pressure and the residue was purified on reverse phase silica eluting with a gradient of 100% 0.1% ammonia in water to 50% 0.1% ammonia in water and 50% 0.1% ammonia in acetonitrile over 15 minutes.
Retention Time Method C 0.95 mins, M+H+=398/400
Retention Time Method B 1.96 mins, M+H+=350/2
Retention Time Method A 1.31 mins, M+H+=380/2
Retention Time Method B 2.04 mins, M+H+=362/4
Retention Time Method B 1.91 mins, M+H+=392/4
Retention Time Method B 2.07 mins, M+H+=386/8
Retention Time Method A 1.27 mins, M+H+=416/8
Retention Time Method B 2.21 mins, M+H+=398/400
Retention Time Method B 1.43 mins, M+H+=428/30
Retention Time Method C 0.72 mins, M+H+=336/8
Retention Time Method C 0.65 mins, M+H+=366/8
Retention Time Method C 0.75 mins, M+H+=372/4
Retention Time Method C 0.95 mins, M+H+=398/400
Retention Time Method C 0.69 mins, M+H+=350/2
Retention Time Method C 0.67 mins, M+H+=380/2
Retention Time Method C 0.71 mins, M+H+=362/4
Retention Time Method C 0.69 mins, M+H+=392/4
Retention Time Method C 0.72 mins, M+H+=486/8
Retention Time Method C 0.93 mins, M+H+=398/400
Retention Time Method C 0.69 mins, M+H+=350/2
Retention Time Method C 0.67 mins, M+H+=380/2
Retention Time Method C 0.71 mins, M+H+=362/4
Retention Time Method C 0.69 mins, M+H+=392/4
Retention Time Method C 0.72 mins, M+H+=486/8
Retention Time Method C 0.93 mins, M+H+=398/40
Retention Time Method C 0.73 mins, M+H+=364/6
Retention Time Method C 0.70 mins, M+H+=94/6
Retention Time Method C 0.75 mins, M+H+=376/8
Retention Time Method C 0.72 mins, M+H+=406/8
Retention Time Method C 0.75 mins, M+H+=400/2
Retention Time Method C 0.72 mins, M+H+=430/2
Retention Time Method C 0.97 mins, M+H+=412/4
Retention Time Method C 0.73 mins, M+H+=364/6
Retention Time Method C 0.70 mins, M+H+=94/6
Retention Time Method C 0.75 mins, M+H+=376/8
Retention Time Method C 0.72 mins, M+H+=406/8
Retention Time Method C 0.75 mins, M+H+=400/2
Retention Time Method C 0.72 mins, M+H+=430/2
Retention Time Method C 0.97 mins, M+H+=412/4
Intermediate 19 (30 mg) was dissolved in isopropyl alcohol (1 ml) and heated for 30 mins at 140° C. in a microwave with 1-methyl-1H-pyrazol-4-amine (12 mg) and two drops of 4M hydrogen chloride in 1,4 dioxan. The reaction was cooled, diluted with ethyl acetate (2 ml) and the resultant precipitate collected by filtration and dried in vacuo to give the title compound.
Retention Time Method C 0.96 mins, M+H+=323/5
Was prepared according to the method of example 46 from intermediate 20
Retention Time Method C 0.95 mins, M+H+=321/323
Intermediate 21 (50 mg, 0.16 mmol) was partially dissolved in dichloromethane (2 mL) and bromo ethanol (0.18 mmol) and triethylamine (0.34 mmol) were added. The reaction mixture was stirred at r.t. for approx. 18 h. Potassium carbonate (0.16 mmol) was added and the mixture stirred at r.t. for 18 h. The reaction mixture was filtered and the filter cake washed with dichloromethane. The filtrate was concentrated in vacuo and the residue purified by prep. HPLC at high pH.
Retention Time Method B 6.95 mins, M+H+=352
Intermediate 21 (30 mg, 0.10 mmol) was suspended in acetonitrile and 3-bromopropionitrile (0.11 mmol) and potassium carbonate (0.22 mmol) were added. The reaction mixture was stirred at r.t. for 18 h. Potassium carbonate (0.22 mmol) and 3-bromopropionitrile (0.11 mmol) were added and the mixture stirred at r.t for 48 h. The reaction mixture was filtered and the filter cake washed with dichloromethane. The filtrate was concentrated in vacuo and the residue purified by prep. HPLC at high pH.
Retention Time Method B 8.04 mins, M+H+=361
Prepared from intermediate 21 in a similar manner to example 48 using 1-chloro-2-(methylsulfonyl)ethane.
Retention Time Method B 7.43 mins, M+H+=414
Intermediate 21 (30 mg, 0.10 mmol) was partially dissolved in dichloromethane and ethanesulfonyl chloride (0.11 mmol) and triethylamine (0.21 mmol) were added. The reaction mixture was stirred at r.t. for 16 h. Triethylamine (0.21 mmol) and ethanesulfonyl chloride (0.11 mmol) were added and the mixture stirred at r.t. for 18 h. The reaction mixture was concentrated in vacuo and the residue purified by prep. HPLC at high pH.
Retention Time Method B 7.65 mins, M+H+=400
Intermediate 21 (30 mg, 0.10 mmol), cyanoacetic acid (0.11 mmol), HATU (0.13 mmol) and DIPEA (0.23 mmol) were dissolved in DMF and the mixture stirred at r.t. for 12 h. DIPEA (0.23 mmol) was added and the mixture stirred at r.t. for 18 h. The reaction mixture was diluted with dichloromethane, washed with water, dried using a hydrophobic frit then concentrated in vacuo. The residue was purified by prep. HPLC at high pH.
Retention Time Method B 6.93 mins, M+H+=375
Prepared from intermediate 21 in a similar manner to example 52 using N,N-dimethylglycine.
Retention Time Method B 6.95 mins, M+H+=393
Prepared from intermediate 21 in a similar manner to example 52 using glycolic acid.
Retention Time Method B 6.47 mins, M+H+=366
Prepared from intermediate 23 in a similar manner to example 48 using 1-chloro-2-(methylsulfonyl)ethane.
Retention Time Method B 6.84 mins, M+H+=414
Prepared from intermediate 23 in a similar manner to example 48 using bromoethanol.
Retention Time Method B 6.84 mins, M+H+=414
Prepared from intermediate 23 in a similar manner to example 48.
Retention Time Method B 7.35 mins, M+H+=361
Prepared from intermediate 23 in a similar manner to example 52.
Retention Time Method B 6.65 mins, M+H+=365
Prepared from intermediate 23 in a similar manner to example 52 using N,N-dimethylglycine.
Retention Time Method B 6.66 mins, M+H+=393
2,4,5-trichloropyrimidine (150 mg, 0.82 mmol), (S)-(−)-amino methyl-1-ethylpyrrolidine (0.9 mmol) and DIPEA (1.39 mmol) were dissolved in isopropanol (5 mL) and the mixture stirred at 60° C. for 2 h. The reaction mixture was diluted with dichloromethane, washed with water, dried using a hydrophobic frit and concentrated in vacuo to afford (R)-2,5-dichloro-N-((1-ethylpyrrolidin-2-yl)methyl)pyrimidin-4-amine as a yellow gum.
(R)-2,5-dichloro-N-((1-ethylpyrrolidin-2-yl)methyl)pyrimidin-4-amine (50 mg, 0.18 mmol) and 1-Methyl-1H-pyrazolo-4-ylamine (0.20 mmol) were dissolved in isopropanol (5 mL) and 4M HCl in Dioxane (0.29 mmol) added. The reaction was heated at 120° C. in a microwave. The reaction mixture was diluted with dichloromethane, washed with water, dried using a hydrophobic frit and concentrated in vacuo. The residue was purified by prep. HPLC at high pH.
Retention Time Method B 8.68 mins, M+H+=336
Prepared in a similar manner to example 60 using (R)-(−)-aminomethyl-1-ethylpyrrolidine.
Retention Time Method B 8.70 mins, M+H+=336
Prepared in a similar manner to example 60 using rac-4-aminomethyl-1-methylpyrrolidine.
Retention Time Method B 7.83 mins, M+H+=322
Intermediate 1 (300 mg, 0.87 mmol) and 2-(4-amino-1H-pyrazol-1-yl)-N-methylacetamide (0.96 mmol) were dissolved in isopropanol and 4M HCl in dioxane (1.39 mmol) added. The mixture was heated at 120° C. for 30 mins in a microwave. The reaction mixture was concentrated in vacuo and purified by prep. HPLC at high pH.
Retention Time Method B 7.15 mins, M+H+=365
Prepared in a similar manner to example 63 using 2-(4-amino-1H-pyrazol-1-yl)-N-dimethylacetamide.
Retention Time Method B 7.87 mins, M+H+=379
Prepared in a similar manner to example 63 using intermediate 2.
Retention Time Method B 7.23 mins, M+H+=365
Prepared in a similar manner to example 63 using intermediate 2.
Retention Time Method B 7.97 mins, M+H+=379
(R)-2-(4-(5-chloro-4-(pyrrolidin-2-ylmethylamino)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)-N-methylacetamide (46 mg, 0.13 mmol) was partially dissolved in dichloromethane and methanesulfonyl chloride (0.14 mmol) and triethylamine (0.14 mmol) added. The reaction mixture was stirred at r.t. for 15 h. Methanesulfonyl chloride (0.14 mmol) and triethylamine (0.14 mmol) were added and the mixture stirred at r.t. for 18 h. The reaction mixture was concentrated in vacuo and purified by prep. HPLC at high pH.
Retention Time Method B 6.60 mins, M+H+=443
Prepared in a similar manner to example 67 using (R)-2-(4-(5-chloro-4-(pyrrolidin-2-ylmethylamino)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)-N,N-dimethylacetamide.
Retention Time Method B 6.80 mins, M+H+=457
Prepared in a similar manner to example 67 using (S)-2-(4-(5-chloro-4-(pyrrolidin-2-ylmethylamino)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)-N,N-dimethylacetamide.
Retention Time Method B 6.84 mins, M+H+=457
Intermediate 24 (100 mg, 0.30 mmol) and 1-methyl-1H-pyrazolo-4-ylamine (0.34 mmol) were dissolved in isopropanol (5 mL) and 4M HCl in Dioxane (0.5 mmol) added. The reaction was heated at 120° C. for 30 min in a microwave. The reaction mixture was filtered and the filter cake washed with isopropanol and diethyl ether.
Retention Time Method B 7.22 mins, M+H+=292
Prepared in a similar manner to example 70 using intermediate 25.
Retention Time Method B 7.28 mins, M+H+=292
Prepared in a similar manner to example 70 using intermediate 26.
Retention Time Method B 8.09, M+H+=288
Prepared in a similar manner to example 70 using intermediate 27.
Retention Time Method B 8.13 mins, M+H+=288
(R)-5-fluoro-N2-(1-methyl-1H-pyrazol-4-yl)-N4-(pyrrolidin-2-ylmethyl)pyrimidine-2,4-diamine Hydrochloride (42 mg, 0.14 mmol) was partially dissolved in dichloromethane and methane sulfonyl chloride (0.15 mmol) and triethylamine (0.30 mmol) added. The mixture was stirred at r.t. for 15 h. The reaction mixture was diluted with dichloromethane, washed with water, dried using a hydrophobic frit and concentrated in vacuo. The residue was dissolved in methanol and passed onto a SCX cartridge. The cartridge was washed with methanol then eluted with HCl in methanol. The eluted solution was concentrated in vacuo to afford the title compound as a yellow solid.
Retention Time Method B 6.83 mins, M+H+=370
Prepared in a similar manner to example 74 using (S)-5-fluoro-N2-(1-methyl-1H-pyrazol-4-yl)-N4-(pyrrolidin-2-ylmethyl)pyrimidine-2,4-diamine Hydrochloride.
Retention Time Method B 6.83 mins, M+H+=370
Prepared in a similar manner to example 67 using (R)-5-methyl-N2-(1-methyl-1H-pyrazol-4-yl)-N4-(pyrrolidin-2-ylmethyl)pyrimidine-2,4-diamine Hydrochloride.
Retention Time Method B 6.77 mins, M+H+=366
Prepared in a similar manner to example 67 using (S)-5-methyl-N2-(1-methyl-1H-pyrazol-4-yl)-N4-(pyrrolidin-2-ylmethyl)pyrimidine-2,4-diamine Hydrochloride.
Retention Time Method B 6.75 mins, M+H+=366
Prepared in a similar manner to example 46 using intermediate 28.
Retention Time Method B 6.25 mins, M+H+=336
Prepared in a similar way to example 63 using intermediate 4 and 2-(4-amino-1H-pyrazol-1-yl)ethanol.
Retention Time Method B 7.39 mins, M+H+=338
Prepared in a similar way to example 48 using intermediate 21 and 1,1,1-trifluoro-3-iodopropane.
Retention Time Method B 9.83 mins, M+H+=404
Prepared in a similar way to example 48 using intermediate 22 and 3-bromopropanenitrile
Retention Time Method B 8.10 mins, M+H+=361
Prepared in a similar way to example 48 using intermediate 22 and 1-chloro-2-(methylsulfonyl)ethane
Retention Time Method B 7.38 mins, M+H+=414
Prepared in a similar way to example 48 using intermediate 30 and 3-bromopropanenitrile
Retention Time Method B 7.08 mins, M+H+=412
Prepared in a similar way to example 48 using intermediate 30 and 1-chloro-2-(methylsulfonyl)ethane
Retention Time Method B 6.66 mins, M+H+=465
(R)-2-(4-((5-chloro-4-(((1-(methylsulfonyl)pyrrolidin-3-yl)methyl)amino)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)ethanol was prepared by heating intermediate 31 (233 mg) and 2-(4-amino-1H-pyrazol-1-yl)ethanol (100 mg) in propan-2-ol (2 ml) with 4M hydrogen chloride in dioxan (100 ul) at 120° C. in a microwave for 30 minutes. The product was purified by preparative hplc.
Retention Time Method B 6.45 mins, M+H+=416
Prepared from intermediate 21 using a similar method to example 52 and 3-cyanopropanoic acid
Retention Time Method B 7.09 mins, M+H+=389
Was prepared from intermediate 33 in a similar method to example 48 using 1-chloro-2-(methylsulfonyl)ethane
Retention Time Method B 6.67 mins, M+H+=430
Was prepared from intermediate 21 as follows. Intermediate 21 (30 mg) and triethylamine (30 ul) were dissolved in dichloromethane (5 ml) and stirred. Ethyl isocyanate (10 ul) was added and the reaction stirred for 2 hours. The reaction mixture was washed with 1M citric acid and water and the phases separated. The organic phase was concentrated under reduced pressure to give example 88.
Retention Time Method B 7.28 mins, M+H+=379
Was prepared in a similar manner to example 88 using cyclopropyl isocyanate
Retention Time Method B 7.24 mins, M+H+=391
Was prepared from intermediate 35 using a similar method to example 48
Retention Time Method A 2.17 mins, M+H+=379
Was prepared from intermediate 35 using a similar method to example 48
Retention Time Method B 7.22 mins, M+H+=432
Was prepared from intermediate 22 in a similar manner to example 52
Retention Time Method B 7.09 mins, M+H+=389
Was prepared from intermediate 36 using a similar method to example 52 and 3-cyanopropanoic acid
Retention Time Method B 6.23 mins, M+H+=355
Was prepared from intermediate 30 using a similar method to example 52 and 3-cyanopropanoic acid
Retention Time Method B 6.59 mins, M+H+=440
Was prepared from intermediate 36 using a similar method to example 52 and 2-cyanoacetic acid
Retention Time Method A 1.72 mins, M+H+=341
Was prepared from intermediate 30 using a similar method to example 52 and 2-cyanoacetic acid
Retention Time Method B 6.32 mins, M+H+=426
Prepared in a similar way to example 48 using intermediate 21 and 4-bromobutanenitrile.
Retention Time Method B 8.40 mins, M+H+=375
Was prepared from intermediate 21 using a method similar to example 51 and cyclopropanesulfonyl chloride
Retention Time Method B 7.88 mins, M+H+=412
Prepared in a similar way to example 48 using intermediate 21 and 2-chloro-N-(cyanomethyl)acetamide.
Retention Time Method B 7.30 mins, M+H+=404
Prepared from intermediate 38 in a similar manner to example 48 using 1-chloro-2-(methylsulfonyl)ethane.
Retention Time Method B 6.77 mins, M+H+=412
Prepared from intermediate 38 in a similar manner to example 48 using 3-bromopropanenitrile.
Retention Time Method A 2.00 mins, M+H+=359
Prepared from intermediate 38 in a similar manner to example 48 using 2-bromoacetonitrile.
Retention Time Method A 1.92 mins, M+H+=345
Was prepared from intermediate 38 using a similar method to example 52 and 2-cyanoacetic acid
Retention Time Method B 6.50 mins, M+H+=373
Was prepared from intermediate 38 using a similar method to example 52 and 3-cyanopropanoic acid
Retention Time Method A 1.84 mins, M+H+=387
Prepared in a similar way to example 48 using example 73 and 1-chloro-2-(methylsulfonyl)ethane
Retention Time Method B 6.95 mins, M+H+=394
Prepared in a similar way to example 48 using example 73 and 3-bromopropanenitrile
Retention Time Method A 2.05 mins, M+H+=341
Prepared in a similar way to example 48 using example 72 and 1-chloro-2-(methylsulfonyl)ethane
Retention Time Method A 1.93 mins, M+H+=394
Prepared in a similar way to example 48 using example 72 and 3-bromopropanenitrile
Retention Time Method B 7.47 mins, M+H+=341
was prepared in similar manner to example 52 from example 72.
Retention Time Method B 6.51 mins, M+H+=355
was prepared in similar manner to example 52 from intermediate 35 and 3-cyanopropanoic acid.
Retention Time Method B 7.06 mins, M+H+=407
was prepared in similar manner to example 52 from intermediate 40 and 3-cyanopropanoic acid.
Retention Time Method B 6.41 mins, M+H+=369
Was prepared from example 70 and 3-bromopropanenitrile using a similar method to example 48
Retention Time Method B 7.41 mins, M+H+=345
Was prepared from example 70 and 2-cyanoacetic acid using a similar method to example 52
Retention Time Method B 6.60 mins, M+H+=359
Was prepared from example 70 and 3-cyanopropanoic acid using a similar method to example 52
Retention Time Method B 6.75 mins, M+H+=373
Prepared in a similar way to example 48 using intermediate 21 and 3-bromotetrahydrothiophene 1,1-dioxide.
Retention Time Method B 7.45 mins, M+H+=426
Prepared in a similar way to example 48 using intermediate 41 and 1-chloro-2-(methylsulfonyl)ethane.
Retention Time Method B 7.58 mins, M+H+=444
Prepared in a similar way to example 48 using intermediate 41 and 3-bromopropanenitrile.
Retention Time Method B 8.32 mins, M+H+=391
Was prepared from intermediate 41 and 2-cyanoacetic acid using a similar method to example 52
Retention Time Method B 7.19 mins, M+H+=405
Prepared in a similar way to example 48 using intermediate 22 and 1-chloro-3-(methylsulfonyl)propane
Retention Time Method B 7.56 mins, M+H+=428
Prepared in a similar way to example 48 using intermediate 43 and 1-chloro-2-(methylsulfonyl)ethane
Retention Time Method B 7.44 mins, M+H+=462
Prepared in a similar way to example 48 using intermediate 43 and 3-bromopropanenitrile.
Retention Time Method B 7.95 mins, M+H+=409
Was prepared from intermediate 43 and 3-cyanopropanoic acid using a similar method to example 52
Retention Time Method B 7.22 mins, M+H+=437
Prepared in a similar way to example 48 using intermediate 45 and 1-chloro-2-(methylsulfonyl)ethane.
Retention Time Method B 7.63 mins, M+H+=444
Was prepared from intermediate 45 and 2-cyanoacetic acid using a similar method to example 52
Retention Time Method B 7.28 mins, M+H+=405
Was prepared from intermediate 45 and 3-cyanopropanoic acid using a similar method to example 52
Retention Time Method B 7.45 mins, M+H+=419.
Prepared in a similar way to example 48 using example 21 and N-(2-chloroethyl)methanesulfonamide.
Retention Time Method B 7.41 mins, M+H+=429
Prepared in a similar way to example 48 using intermediate 47 and 1-chloro-2-(methylsulfonyl)ethane.
Retention Time Method B 7.12 mins, M+H+=444
Prepared in a similar way to example 48 using intermediate 47 and 3-bromopropanenitrile.
Retention Time Method B 7.31 mins, M+H+=391
Was prepared from intermediate 47 and 2-cyanoacetic acid using a similar method to example 52
Retention Time Method B 6.86 mins, M+H+=405
Was prepared from intermediate 47 and 3-cyanopropanoic acid using a similar method to example 52
Retention Time Method B 6.99 mins, M+H+=419
Prepared in a similar way to example 48 using example 21 and 2-bromoacetonitrile.
Retention Time Method B 7.88 mins, M+H+=347
Prepared in a similar way to example 48 using intermediate 48 and 1-chloro-2-(methylsulfonyl)ethane.
Retention Time Method B 7.45 mins, M+H+=446
Prepared in a similar way to example 48 using intermediate 48 and 4-bromobutanenitrile.
Retention Time Method B 7.95 mins, M+H+=393
Was prepared from intermediate 50 and 2-cyanoacetic acid using a similar method to example 52
Retention Time Method B 7.16 mins, M+H+=389
Was prepared from intermediate 52 and 2-cyanoacetic acid using a similar method to example 52
Retention Time Method B 7.13 mins, M+H+=389
Was prepared from intermediate 52 and 3-cyanopropionic acid using a similar method to example 52
Retention Time Method B 7.28 mins, M+H+=403
Was prepared from intermediate 51 and 2-cyanoacetic acid using a similar method to example 52
Retention Time Method B 7.16 mins, M+H+=389
Was prepared from intermediate 51 and 3-cyanopropionic acid using a similar method to example 52
Retention Time Method B 7.30 mins, M+H+=403
Prepared in a similar way to example 48 using example 21 and 2-((2-chloroethyl)sulfonyl)propane.
Retention Time Method B 8.05 mins, M+H+=442
Determination of the Effect of the Compounds According to the Invention on Janus Kinases (JAK Family) in Kinobeads™ Assays with Immunodetection of Kinases
The compounds of the present invention as described in the previous examples were tested in a Kinobeads™ assay as described for ZAP-70 (WO-A 2007/137867). Briefly, test compounds (at various concentrations) and the affinity matrix with the immobilized aminopyrido-pyrimidine ligand 24 were added to cell lysate aliquots and allowed to bind to the proteins in the lysate sample. After the incubation time the beads with captured proteins were separated from the lysate. Bound proteins were then eluted and the presence of JAK1, JAK2, JAK3 and TYK2 was detected and quantified using specific antibodies in a dot blot procedure and the Odyssey infrared detection system. Dose response curves for individual kinases were generated and IC50 values calculated. Kinobeads™ assays for ZAP-70 (WO-A 2007/137867) and for kinase selectivity profiling (WO-A 2006/134056) have been previously described.
The affinity matrix was washed two times with 15 mL of 1×DP buffer containing 0.2% NP40 (IGEPAL® CA-630, Sigma, #13021) and then resuspended in 1×DP buffer containing 0.2% NP40 (3% beads slurry).
5×DP buffer: 250 mM Tris-HCl pH 7.4, 25% Glycerol, 7.5 mM MgCl2, 750 mM NaCl, 5 mM Na3VO4; filter the 5×DP buffer through a 0.22 μm filter and store in aliquots at −80° C. The 5×DP buffer is diluted with H2O to 1×DP buffer containing 1 mM DTT and 25 mM NaF.
Stock solutions of test compounds were prepared in DMSO. In a 96 well plate 30 μL solution of diluted test compounds at 5 mM in DMSO were prepared. Starting with this solution a 1:3 dilution series (9 steps) was prepared. For control experiments (no test compound) a buffer containing 2% DMSO was used.
Molt4 cells (ATCC catalogue number CRL-1582) and Ramos cells (ATCC catalogue number CRL-1596) were grown in 1 L Spinner flasks (Integra Biosciences, #182101) in suspension in RPMI 1640 medium (Invitrogen, #21875-034) supplemented with 10% Fetal Bovine Serum (Invitrogen) at a density between 0.15×106 and 1.2×106 cells/mL. Cells were harvested by centrifugation, washed once with 1×PBS buffer (Invitrogen, #14190-094) and cell pellets were frozen in liquid nitrogen and subsequently stored at −80° C. Cells were homogenized in a Potter S homogenizer in lysis buffer: 50 mM Tris-HCl, 0.8% NP40, 5% glycerol, 150 mM NaCl, 1.5 mM MgCl2, 25 mM NaF, 1 mM sodium vanadate, 1 mM DTT, pH 7.5. One complete EDTA-free tablet (protease inhibitor cocktail, Roche Diagnostics, 1873580) per 25 ml, buffer was added. The material was dounced 10 times using a mechanized POTTER S, transferred to 50 mL falcon tubes, incubated for 30 minutes on ice and spun down for 10 minutes at 20,000 g at 4° C. (10,000 rpm in Sorvall SLA600, precooled). The supernatant was transferred to an ultracentrifuge (UZ)-polycarbonate tube (Beckmann, 355654) and spun for 1 hour at 100.000 g at 4° C. (33.500 rpm in Ti50.2, precooled). The supernatant was transferred again to a fresh 50 mL falcon tube, the protein concentration was determined by a Bradford assay (BioRad) and samples containing 50 mg of protein per aliquot were prepared. The samples were immediately used for experiments or frozen in liquid nitrogen and stored frozen at −80° C.
Cell lysate (approximately 50 mg protein per plate) was thawed in a water bath at room temperature and then stored on ice. To the thawed cell lysate 1×DP 0.8% NP40 buffer containing protease inhibitors (1 tablet for 25 mL buffer; EDTA-free protease inhibitor cocktail; Roche Diagnostics 1873580) was added in order to reach a final protein concentration of 10 mg/mL total protein. The diluted cell lysate was stored on ice. Mixed Molt4/Ramos lysate was prepared by combining one volume of Molt4 lysate and two volumes of Ramos lysate (ratio 1:2).
Incubation of Lysate with Test Compound and Affinity Matrix
To a 96 well filter plate (Multiscreen HTS, BV Filter Plates, Millipore #MSBVN1250) were added per well: 1004 affinity matrix (3% beads slurry), 3 μL of compound solution, and 50 μL of diluted lysate. Plates were sealed and incubated for 3 hours in a cold room on a plate shaker (Heidolph tiramax 1000) at 750 rpm. Afterwards the plate was washed 3 times with 230 μL washing buffer (1×DP 0.4% NP40). The filter plate was placed on top of a collection plate (Greiner bio-one, PP-microplate 96 well V-shape, 65120) and the beads were then eluted with 20 μL of sample buffer (100 mM Tris, pH 7.4, 4% SDS, 0.00025% bromophenol blue, 20% glycerol, 50 mM DTT). The eluate was frozen quickly at −80° C. and stored at −20° C.
The kinases in the eluates were detected and quantified by spotting on nitrocellulose membranes and using a first antibody directed against the kinase of interest and a fluorescently labelled secondary antibody (anti-rabbit IRDye™ antibody 800 (Licor, #926-32211). The Odyssey Infrared Imaging system from LI-COR Biosciences (Lincoln, Nebr., USA) was operated according to instructions provided by the manufacturer (Schutz-Geschwendener et al., 2004. Quantitative, two-color Western blot detection with infrared fluorescence. Published May 2004 by LI-COR Biosciences, www.licor.com).
After spotting of the eluates the nitrocellulose membrane (BioTrace NT; PALL, #BTNT30R) was first blocked by incubation with Odyssey blocking buffer (LICOR, 927-40000) for one hour at room temperature. Blocked membranes were then incubated for 16 hours at the temperature shown in table 5 with the first antibody diluted in Odyssey blocking buffer (LICOR #927-40000). Afterwards the membrane was washed twice for 10 minutes with PBS buffer containing 0.2% Tween 20 at room temperature. The membrane was then incubated for 60 minutes at room temperature with the detection antibody (anti-rabbit IRDye™ antibody 800, Licor, #926-32211) diluted in Odyssey blocking buffer (LICOR #927-40000). Afterwards the membrane was washed twice for 10 minutes each with 1×PBS buffer containing 0.2% Tween 20 at room temperature. Then the membrane was rinsed once with PBS buffer to remove residual Tween 20. The membrane was kept in PBS buffer at 4° C. and then scanned with the Odyssey instrument. Fluorescence signals were recorded and analysed according to the instructions of the manufacturer.
Table 5 provides data for selected compounds of the invention in the JAK Kinobeads™ assay.
| Number | Date | Country | Kind |
|---|---|---|---|
| 11195662.9 | Dec 2011 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2012/076371 | 12/20/2012 | WO | 00 |
